166 related articles for article (PubMed ID: 24327524)
1. Pretreatment neutrophil-to-lymphocyte ratio as predictor of survival for patients with metastatic nasopharyngeal carcinoma.
Jin Y; Ye X; He C; Zhang B; Zhang Y
Head Neck; 2015 Jan; 37(1):69-75. PubMed ID: 24327524
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Neutrophil to Lymphocyte Ratio, Lymphocyte to Monocyte Ratio, and Platelet to Lymphocyte Ratio in Patients with Nasopharyngeal Carcinoma.
Lu A; Li H; Zheng Y; Tang M; Li J; Wu H; Zhong W; Gao J; Ou N; Cai Y
Biomed Res Int; 2017; 2017():3047802. PubMed ID: 28321405
[TBL] [Abstract][Full Text] [Related]
3. Combined pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts survival and prognosis in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
Yang D; Li P; Meng Z; Hu X; Huang Z; Huang H; Dong H; Qin Y; Chen C; Chen X; Li Z; Zhou Z; Li Y; Kang M
Sci Rep; 2024 Apr; 14(1):9898. PubMed ID: 38688967
[TBL] [Abstract][Full Text] [Related]
4. Cutoff point of neutrophil-to-lymphocyte ratio for predicting survival in nasopharyngeal carcinoma.
Setakornnukul J; Chanvimalueng W; Patumanond J; Thephamongkhol K
Medicine (Baltimore); 2021 Aug; 100(34):e27095. PubMed ID: 34449514
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma.
He JR; Shen GP; Ren ZF; Qin H; Cui C; Zhang Y; Zeng YX; Jia WH
Head Neck; 2012 Dec; 34(12):1769-76. PubMed ID: 22318781
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.
Sun W; Zhang L; Luo M; Hu G; Mei Q; Liu D; Long G; Hu G
Head Neck; 2016 Apr; 38 Suppl 1():E1332-40. PubMed ID: 26362911
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in nasopharyngeal carcinoma: A retrospective study of 180 Taiwanese patients.
Liao LJ; Hsu WL; Wang CT; Lo WC; Cheng PW; Shueng PW; Hsieh CH; Chiu YL; Lin YC
Clin Otolaryngol; 2018 Apr; 43(2):463-469. PubMed ID: 28950051
[TBL] [Abstract][Full Text] [Related]
8. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma.
Chen C; Sun P; Dai QS; Weng HW; Li HP; Ye S
PLoS One; 2014; 9(11):e112581. PubMed ID: 25393117
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis.
Takenaka Y; Kitamura T; Oya R; Ashida N; Shimizu K; Takemura K; Yamamoto Y; Uno A
PLoS One; 2017; 12(7):e0181478. PubMed ID: 28715474
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis.
Su L; Zhang M; Zhang W; Cai C; Hong J
Medicine (Baltimore); 2017 Mar; 96(11):e6364. PubMed ID: 28296774
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area.
Yao JJ; Zhu FT; Dong J; Liang ZB; Yang LW; Chen SY; Zhang WJ; Lawrence WR; Zhang F; Wang SY; Sun Y; Zhou GQ
BMC Cancer; 2019 Jan; 19(1):37. PubMed ID: 30621619
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma.
Ye M; Huang A; Yuan B; Tan G; Ai J; Liu H
Eur Arch Otorhinolaryngol; 2024 Apr; 281(4):1971-1989. PubMed ID: 38315178
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
Ye L; Oei RW; Kong F; Xu T; Shen C; Wang X; He X; Kong L; Hu C; Ying H
Eur Arch Otorhinolaryngol; 2018 May; 275(5):1309-1317. PubMed ID: 29589142
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of neutrophil-to-lymphocyte ratio for nasopharyngeal carcinoma: A meta-analysis.
Yin J; Qin Y; Luo YK; Feng M; Lang JY
Medicine (Baltimore); 2017 Jul; 96(29):e7577. PubMed ID: 28723793
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in older patients with metastatic cancer.
Chen KH; Tsang NM; Chou WC; Tai SF; Liu SC; Lei KF; Chang KP; Chuang WC; Pai PC
J Geriatr Oncol; 2019 Sep; 10(5):757-762. PubMed ID: 31085137
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
[TBL] [Abstract][Full Text] [Related]
18. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus.
Toh E; Wilson J; Sebag-Montefiore D; Botterill I
Colorectal Dis; 2014 Mar; 16(3):O90-7. PubMed ID: 24148256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
